

Attorney Docket No. NASH-001/03US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 4, 2003.



By:


Vladimir Skliba

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Thomas M. VAUGHN et al. Examiner: Unassigned

Serial No.: 10/601,314 Art Unit: 1614

Filed: June 20, 2003 Confirmation No.: 6959

For: METHODS OF MAKING AND USING THEAFLAVIN, THEAFLAVIN-3-GALLATE, THEAFLAVIN-3'-GALLATE AND THEAFLAVIN 3,3'-DIGALLATE AND MIXTURES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Transmitted herewith are:

1. Information Disclosure Statement under 37 CFR §1.97(b)
2. PTO/SB/08A
3. PCT Search Report
4. 8 references (A4-A10 and B1)
5. Return receipt postcard

In accordance with 37 C.F.R. §1.97(b), no fee for submission of the IDS is required.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated: November 4, 2003

Respectfully submitted,
COOLEY GODWARD LLP

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000
Fax: (650) 857-0663

By:


Sunil K. Singh
Reg. No. 45,298

This Information Disclosure Statement is filed before the mailing date of a first office action on the merits.


It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: November 4, 2003

Respectfully submitted,
COOLEY GODWARD LLP

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000
Fax: (650) 857-0663

By:


Sunil K. Singh
Reg. No. 45,298

Please type a plus sign (+) inside this box ➔



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/601,314
				Filing Date	June 20, 2003
				First Named Inventor	Thomas M. VAUGHN
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	
NASH-001/03US					

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.


³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known
Sheet	2	of	2	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name
				10/601,314 June 20, 2003 Thomas M. VAUGHN 1614 Unassigned
				Attorney Docket Number NASH-001/03US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ALDERMAN D. A., "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," <i>Int. J. Pharm. Tech. Prod. Mfr.</i> 5(3):1-9, 1984	
	C2	BAMBA et al., "Release mechanisms in gel forming sustained release preparations," <i>Int. J. Pharm.</i> 2:307, 1979	
	C3	BERGE et al., <i>J. Pharm. Sci.</i> 66:1-19, 1977	
	C4	LEUNG et al., "Theaflavins in Black Tea and Catechins in Green Tea Are Equally Effective Antioxidants," <i>J. Nutr.</i> 131(9):2248-2251, 2001	
	C5	SARKAR et al., <i>Biochem. Biophys. Res. Commun.</i> 284(1):173-178, 2001	
	C6	VERMA et al., <i>Drug Dev. Ind. Pharm.</i> 26:695-708, 2000	
	C7	YOSHINO et al., <i>Biol. Pharm. Bull.</i> 17(1):146-149, 1994	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.